Healthcare Wrap: Contracts and approvals send diagnostics and medtech higher

• Genetic Signatures led the sector after landing a 10-year Danish diagnostics contract.
• Immutep surged on rare disease status from the FDA, which can bring years of market protection if a drug is later approved.
• Orthocell extended its US push from hospital access to actual surgery, helping keep buying interest alive.
• Telix announced both a major cancer partnership and a US$550 million debt refinancing, but early enthusiasm faded after the stock reopened.